Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

SAR439459

Phase 2Small molecule

SAR439459 is one of 37 small molecule programs targeting Age. It is currently in Phase 2.

1

Indications

3

Total Trials

1

Active Trials

36

Competitors

Pipeline

Status by Indication[3][1]

Indication

AgeRecruiting

AgePhase 2

Recruiting

Competition

Competitive Landscape

49 competitors in Age

#DrugCompanyPhaseTrials

Actigall

Rapamune

PPrism Pharmaceuticals

Decadron

AAspen Global Incorporated

Sarclisa

AAzienda U.S.L. 1 di Massa e Carrara

Rezurock

KKadmon, a Sanofi Company

Venclexta

Acotiamide

Evorpacept

AALX Oncology Inc.

APG-2575

Ascentage Pharma Group Inc.

APG-115

Ascentage Pharma Group Inc.

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 1/2Recruiting

Age

NCT04643002

Clinical

Trials by Indication[1]

Osteogenesis Imperfecta1 trial

Single Ascending Dose Study of SAR439459 in Adults With Osteogenesis Imperfecta (OI)

Terminated· Sanofi logo

Sanofi·Phase 1·NCT05231668·16 enrolled

Age1 trial

Isatuximab in Combination With Novel Agents in RRMM - Master Protocol

Recruiting· Sanofi logo

Sanofi·Phase 1/2·NCT04643002·258 enrolled

Patients With Advanced Solid Tumors1 trial

A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and Cemiplimab in Patients With Advanced Solid Tumors

Completed· Sanofi logo

Sanofi·Phase 1·NCT03192345·161 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for SAR439459. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SAR439459 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SAR439459. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Sanofi

Related News